ERASCA INC. - COMMON

Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting

14 Mar 2023 16:31:00 By Nasdaq GlobeNewswire

Erasca to Present at the Guggenheim Oncology Conference 2023

01 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors

20 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors

13 Dec 2022 08:00:02 By Nasdaq GlobeNewswire

Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib

09 Dec 2022 07:34:39 By Nasdaq GlobeNewswire

Erasca Announces Pricing of Underwritten Offering of Common Stock

09 Dec 2022 07:32:35 By Nasdaq GlobeNewswire

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination

30 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Erasca to Present at Upcoming Investor Conferences

22 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Erasca Reports Third Quarter 2022 Financial Results and Business Updates

09 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination

20 Oct 2022 08:00:02 By Nasdaq GlobeNewswire

Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium

12 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022

26 Sep 2022 08:00:02 By Nasdaq GlobeNewswire

Erasca to Present at the Morgan Stanley Global Healthcare Conference

09 Sep 2022 08:31:53 By Nasdaq GlobeNewswire

Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials

07 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors

24 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers

23 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Erasca Reports Second Quarter 2022 Financial Results and Business Updates

11 Aug 2022 16:05:04 By Nasdaq GlobeNewswire

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination

18 Jul 2022 08:00:00 By Nasdaq GlobeNewswire

Erasca to Present at the 2022 Jefferies Healthcare Conference

03 Jun 2022 09:00:00 By Nasdaq GlobeNewswire